Moreover, natural agents, i.e., punicalagin, revealed therapeutic potential by inhibiting ANXA1 and re-establishing apoptosis–autophagy balance, suggesting that ANXA1 may be a future target in CRC therapy. The gene discussed is ANXA1; the disease is colorectal carcinoma.